PMID- 19209152
OWN - NLM
STAT- MEDLINE
DCOM- 20090311
LR  - 20211203
IS  - 1523-1747 (Electronic)
IS  - 0022-202X (Linking)
VI  - 129
IP  - 3
DP  - 2009 Mar
TI  - Dysregulation of the mTOR pathway secondary to mutations or a hostile 
      microenvironment contributes to cancer and poor wound healing.
PG  - 529-31
LID - 10.1038/jid.2008.441 [doi]
AB  - Either heredity mutations or adverse microenvironment conditions may result in 
      dysregulation of the mammalian target of the rapamycin (mTOR) pathway. The former 
      lead to clinical syndromes such as tuberous sclerosis, Peutz-Jeghers syndrome, 
      and Cowden's disease, which are characterized by hamartomatous growth or cancer. 
      The latter can be associated with poor wound healing as described by Goren et al. 
      (2009, this issue).
FAU - Clark, Richard A F
AU  - Clark RA
AD  - Department of Biomedical Engineering, Stony Brook University, Stony Brook, New 
      York 11794-8165, USA. richard.clark@sunysb.edu
FAU - Pavlis, Michelle
AU  - Pavlis M
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (Tuberous Sclerosis Complex 1 Protein)
RN  - 0 (Tuberous Sclerosis Complex 2 Protein)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.1 (mTOR protein, mouse)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
CON - J Invest Dermatol. 2009 Mar;129(3):752-64. PMID: 18668138
MH  - Animals
MH  - *Gene Expression Regulation, Neoplastic
MH  - Hamartoma/genetics
MH  - Hamartoma Syndrome, Multiple/genetics
MH  - Humans
MH  - Mice
MH  - *Mutation
MH  - Neovascularization, Pathologic
MH  - Peutz-Jeghers Syndrome/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein Kinases/*biosynthesis/*genetics
MH  - TOR Serine-Threonine Kinases
MH  - Tuberous Sclerosis/metabolism
MH  - Tuberous Sclerosis Complex 1 Protein
MH  - Tuberous Sclerosis Complex 2 Protein
MH  - Tumor Suppressor Proteins/metabolism
MH  - *Wound Healing
RF  - 20
EDAT- 2009/02/12 09:00
MHDA- 2009/03/12 09:00
CRDT- 2009/02/12 09:00
PHST- 2009/02/12 09:00 [entrez]
PHST- 2009/02/12 09:00 [pubmed]
PHST- 2009/03/12 09:00 [medline]
AID - S0022-202X(15)34266-4 [pii]
AID - 10.1038/jid.2008.441 [doi]
PST - ppublish
SO  - J Invest Dermatol. 2009 Mar;129(3):529-31. doi: 10.1038/jid.2008.441.